Continue to Site

Drug Discovery and Development

Definitive Healthcare debuts data-agnostic analytics platform for life sciences applications 

By |

Definitive HealthcareDefinitive Healthcare (Nasdaq:DH) has launched the Passport Analytics Suite, a product line intended to facilitate the development, launch and commercialization of life science products.

The Passport Analytics Suite integrates technology from Framingham, Massachusetts-based Definitive Healthcare’s acquisition of Analytical Wizards in February 2022. Analytical Wizards is an advanced analytics company catering to the healthcare market. Having been branded as a ‘Definitive Healthcare company,’ Analytical Wizards will remain a standalone company,

One notable customer of Analytical Wizards is Sanofi (Nasdaq:SNY), which uses its technology to integrate data and run analytics at scale to drive strategic decision-making.

Similarly, the Passport Analytics Suite provides life sciences organizations with tools to establish an analytics-driven on-demand environment at scale.

“With these tools, clients can effectively assess and optimize brand performance and dial in the optimal promotional mix,” said Jason Krantz, founder and CEO of Definitive Healthcare, in a press release. “The Passport Analytics Suite helps clients optimize the entire commercialization process, from early-stage business planning needs through post-launch performance acceleration.”

The Passport Analytics Suite can incorporate data from either cloud or IT infrastructure.

“The Passport Analytics Suite is unique in its ability to combine AI-driven data science methodologies with deep expertise in the life sciences,” said Ram Sharma, founder and CEO of Analytical Wizards. “The Passport Analytics Suite delivers configurable analytics on-demand, allowing clients to cut and re-cut data as they want in a secure, self-service environment. The easy-to-use products enable team members from across an organization to create value by reporting on a single source of truth, and then looking at it from multiple angles.”

Filed Under: Data science
Tagged With: ,
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Tell Us What You Think!

Related Articles Read More >

Search Drug Discovery & Development